Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 509

Results For "PAT"

6826 News Found

Ardelyx gets into $20 million financing agreement with HealthCare Royalty Partners
News | July 02, 2022

Ardelyx gets into $20 million financing agreement with HealthCare Royalty Partners

HealthCare Royalty Partners funding supports the ongoing launch of IBSRELA in the United States


Biosynth Carbosynth expands peptide offering with acquisition of Pepscan
News | July 01, 2022

Biosynth Carbosynth expands peptide offering with acquisition of Pepscan

Addition of Pepscan with its peptide discovery, lead optimization and GMP manufacturing capabilities provides end-to-end offering to Biosynth Carbosynth’s peptide customers.


Zydus receives final approval from USFDA for Lacosamide injection
Drug Approval | July 01, 2022

Zydus receives final approval from USFDA for Lacosamide injection

Lacosamide Injection is used to treat partial-onset seizures.


Akebia Therapeutics regaining rights to Vadadustat in the US, Europe and China
News | July 01, 2022

Akebia Therapeutics regaining rights to Vadadustat in the US, Europe and China

Companies finalize termination with an agreed-upon settlement fee of $55M to be paid to Akebia


Biologicals have emerged as a therapy of choice where traditional chemical drugs fail: Dr Bharati Pravin Pawar
Policy | July 01, 2022

Biologicals have emerged as a therapy of choice where traditional chemical drugs fail: Dr Bharati Pravin Pawar

National Institute of Biologicals should undertake the testing of more biologicals and also extend its testing expertise in helping other countries


NADMED brings first CE-marked NAD+ analysis kit to the market
Medical Device | June 30, 2022

NADMED brings first CE-marked NAD+ analysis kit to the market

NADMED technology is based on proprietary extraction and the individual measurement of NAD metabolites


Weizmann’s study sheds new light on a promising antidepressant
Healthcare | June 30, 2022

Weizmann’s study sheds new light on a promising antidepressant

A newly revealed mechanism by Weizmann Institute of Science of ketamine’s action on potassium channels in neurons may lead to improved therapies for depression


MTPA announces long-term findings from post-marketing safety study of Radicava
News | June 30, 2022

MTPA announces long-term findings from post-marketing safety study of Radicava

Analysis of Post-Marketing Safety Data Shows Consistent Findings with Safety Profile Reported in Clinical Trials of Edaravone


Govt calls upon states to step up vigil against Covid
Policy | June 29, 2022

Govt calls upon states to step up vigil against Covid

States were also strongly advised to strictly monitor epidemiological profile of admitted COVID patients


Glenmark Pharmaceuticals expand its OTC portfolio
News | June 29, 2022

Glenmark Pharmaceuticals expand its OTC portfolio

The over-the-counter market has long been an important segment of Glenmark’s portfolio around the world